Isomorphic Labs

Isomorphic Labs is a drug discovery company founded by Google DeepMind CEO Demis Hassabis in 2021, operating as a subsidiary of Alphabet. The company applies AI to transform the pharmaceutical drug discovery process — one of the most expensive and time-consuming challenges in science.

Isomorphic Labs' core technology builds on DeepMind's AlphaFold breakthrough in protein structure prediction. The company has developed IsoDDE (Isomorphic Drug Design Engine), which scientists have dubbed "AlphaFold 4" for its ability to predict not just protein structures but also how drug molecules will bind to protein targets, how they will be metabolized, and their potential side effects — dramatically accelerating the early stages of drug design.

Isomorphic Labs has signed major partnerships with Eli Lilly and Novartis, two of the world's largest pharmaceutical companies, validating its AI-first approach to drug discovery. The company represents Alphabet's bet that the same AI techniques that solved protein folding can transform the broader pharmaceutical R&D process — potentially reducing the average 10-15 year, $2 billion drug development timeline to a fraction of that cost and time.